CMRX vs. VSTM, SCPH, FBIO, CHMA, AQST, NKTX, NBTX, URGN, QTTB, and AVIR
Should you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Verastem (VSTM), scPharmaceuticals (SCPH), Fortress Biotech (FBIO), Chiasma (CHMA), Aquestive Therapeutics (AQST), Nkarta (NKTX), Nanobiotix (NBTX), UroGen Pharma (URGN), Q32 Bio (QTTB), and Atea Pharmaceuticals (AVIR). These companies are all part of the "medical" sector.
Verastem (NASDAQ:VSTM) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, dividends and community ranking.
Verastem currently has a consensus price target of $26.50, indicating a potential upside of 559.20%. Chimerix has a consensus price target of $8.50, indicating a potential upside of 808.61%. Given Verastem's higher probable upside, analysts plainly believe Chimerix is more favorable than Verastem.
Verastem received 211 more outperform votes than Chimerix when rated by MarketBeat users. Likewise, 65.25% of users gave Verastem an outperform vote while only 63.80% of users gave Chimerix an outperform vote.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -25,337.96%. Verastem's return on equity of -41.32% beat Chimerix's return on equity.
88.4% of Verastem shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 2.2% of Verastem shares are held by insiders. Comparatively, 13.1% of Chimerix shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
In the previous week, Verastem had 20 more articles in the media than Chimerix. MarketBeat recorded 24 mentions for Verastem and 4 mentions for Chimerix. Verastem's average media sentiment score of 1.02 beat Chimerix's score of 0.16 indicating that Chimerix is being referred to more favorably in the news media.
Verastem has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Chimerix has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500.
Chimerix has lower revenue, but higher earnings than Verastem. Chimerix is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Summary
Chimerix beats Verastem on 9 of the 17 factors compared between the two stocks.
Get Chimerix News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CMRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chimerix Competitors List
Related Companies and Tools
